SUI Health - Serving Us Individually

Every patient's ALS is different

More than 40 genes have been linked to ALS, affecting processes as diverse as protein degradation, RNA metabolism, and axonal transport. Even patients with the same genetic mutation can have vastly different disease courses. Two people in the same clinic may share a diagnosis but have almost nothing in common at the molecular level.

One-size-fits-all treatment has not worked

Over 70 drugs have been tested in major ALS clinical trials. The vast majority have failed, not necessarily because the drugs don't work, but because they were tested across populations so diverse that any real therapeutic signal was drowned out by biological noise. Effective treatments may already exist but remain invisible when tested in broad, mixed populations.

The biology demands an individual approach

At the molecular level, up to 97% of ALS patients share one common feature: the pathological aggregation of TDP-43 protein, which mislocalizes from the nucleus to the cytoplasm in motor neurons. But how a patient arrives at that pathology, which upstream pathways are disrupted, and which therapeutic interventions can reverse or slow the process differ from patient to patient. We need to move beyond asking "does this drug work for ALS?" and start asking "does this drug work for this patient's ALS?"

The technology exists today

From a small sample of blood or skin, a patient's cells can be reprogrammed into motor neurons, the very cells lost in ALS. These lab-grown neurons carry the patient's complete genetic makeup and behave like their own cells would. Using advanced automated microscopy, we can track thousands of individual neurons over days to weeks, observe what's going wrong, and test candidate treatments directly against that patient's biology.

This is what SUI Health was built to do

SUI Health exists to close the gap between what the science makes possible and what patients actually receive. We are building a personalized therapeutic screening platform that takes each patient's own neurons, identifies the molecular drivers of their disease, and screens FDA-approved drugs with established human safety data against their individual biology.

Every ALS patient deserves to know which therapies have the best chance of working for them: not on average, not in a mouse, but in their own cells. That is what personalized medicine means, and that is what we are building.